Reviewed by Michael Gill, B. Sc.
25 Lymphedema Clinical Trials Near Me
Top Hospitals for Lymphedema Clinical Trials
Image of M D Anderson Cancer Center in Texas.
M D Anderson Cancer Center
Houston
3Active Trials
4All Time Trials for Lymphedema
2012First Lymphedema Trial
Image of Cross Cancer Institute in Alberta.
Cross Cancer Institute
Edmonton
2Active Trials
5All Time Trials for Lymphedema
2003First Lymphedema Trial
Top Treatments for Lymphedema Clinical Trials
Treatment Name
Active Lymphedema Clinical Trials
All Time Trials for Lymphedema
First Recorded Lymphedema Trial
Quality-of-Life Assessment
2
6
2007
Dayspring Active Wearable Compression System
2
2
2021
Cross over Device (PCD or Dayspring - alternate to first group)
1
1
2022
Axillary lymphadenetomy alone
1
1
2021
Constructive Shearwave Interference (CSI)
1
1
2022

What Are Lymphedema Clinical Trials?

Lymphedema is the swelling of tissue as a result of an accumulation of fluid rich in protein. This fluid is typically drained from the lymphatic system of the body. Lymphedema usually affects the legs or arms but may also occur in the genitals, neck, abdomen, and chest wall.

Since lymph nodes are an essential component of the lymphatic system, Lymphedema could also occur due to those cancer treatments that damage or remove the lymph nodes. Any issue that blocks the lymph fluid drainage could lead to Lymphedema.

Severe cases can significantly impact the movement capability of the affected limb, result in skin breakdown and changes, and increase the sepsis and skin infection risk.

Why Is Lymphedema Being Studied Through Clinical Trials?

Primary Lymphedema is a rare disease and can affect one in 100,000 people, but secondary Lymphedema is more common, affecting 1 in 1,000 individuals. One in every five breast cancer surviving women can develop Lymphedema.

In neck and head cancer, soft and lymphatic complications may develop during the initial 18 months of treatment, with over 90% of patients going through a particular type of combined, external, or internal Lymphedema. More than half of these patients might develop fibrosis.

What Are The Types of Treatments Available For Lymphedema?

There isn’t any cure for Lymphedema, which is the reason clinical trials are integral. However, treatments are available to help patients manage the swelling and prevent it from worsening. These treatments include:

  • Surgery is required for severe Lymphedema
  • Cancer treatment in case the cancerous tumor has caused Lymphedema
  • Weight loss is suggested for patients with Lymphedema linked to breast cancer
  • A pneumatic pump inflates the sleeve that is placed on a swollen leg or arm to drain the fluid
  • Exercising also helps in reducing swelling and draining the lymph fluid
  • Massage therapy, particularly manual lymph drainage, helps in draining the lymph fluid from the swollen areas of the body
  • Compression stocking or sleeve aids with swollen leg or arm

What Are Some Recent Breakthrough Clinical Trials For Lymphedema?

2020: The advancement in lymphatic super-microsurgery has shown promising results. The researchers tracked the surgical outcomes in the lymphaticovenular anastomosis (LVA) cases, tracking indocyanine green (ICG) lymphography, limb volume measurement, and clinical examinations. The results indicated that all patients had no signs of limb edema, and there was evidence of improvement. This study suggested that full reversal of Lymphedema is possible with super-microsurgery intervention.

2018: A study uncovered one of the primary molecular mechanism triggers for Lymphedema and found a drug that could prevent this process. The researchers found that the lymph fluid buildup was the inflammatory reaction within the skin tissue. This was caused by leukotriene B4, or LTB4, a natural inflammatory-causing substance. The scientists targeted the LTB4 using pharmacological agents in mice and induced the reversal and repair of the disease.

Who Are Some Of The Key Opinion Leaders / Researchers / Institutions Conducting Lymphedema Clinical Trials Research?

Lymphatic Education & Research Network: It is a non-profit institution created to fight Lymphedema and other lymphatic diseases through advocacy, research, and education.

Center for Lymphatic and Venous Disorders: This Stanford institution diligently works to research and find innovative therapeutic and diagnostic treatments for Lymphedema and other lymphatic diseases by conducting clinical trials, funding research, and spreading awareness.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 30th, 2021

Last Reviewed: November 4th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Andersen KG, Kehlet H. Persistent pain after breast cancer treatment: a critical review of risk factors and strategies for prevention. J Pain. 2011 Jul;12(7):725-46. doi: 10.1016/j.jpain.2010.12.005. Epub 2011 Mar 24. Review. https://pubmed.ncbi.nlm.nih.gov/214359532 Wallace MS, Wallace AM, Lee J, Dobke MK. Pain after breast surgery: a survey of 282 women. Pain. 1996 Aug;66(2-3):195-205. https://pubmed.ncbi.nlm.nih.gov/88808413 Hidding JT, Beurskens CH, van der Wees PJ, van Laarhoven HW, Nijhuis-van der Sanden MW. Treatment related impairments in arm and shoulder in patients with breast cancer: a systematic review. PLoS One. 2014 May 9;9(5):e96748. doi: 10.1371/journal.pone.0096748. eCollection 2014. Review. https://pubmed.ncbi.nlm.nih.gov/248167744 Crescenzi R, Donahue PMC, Hartley KG, Desai AA, Scott AO, Braxton V, Mahany H, Lants SK, Donahue MJ. Lymphedema evaluation using noninvasive 3T MR lymphangiography. J Magn Reson Imaging. 2017 Nov;46(5):1349-1360. doi: 10.1002/jmri.25670. Epub 2017 Feb 28. https://pubmed.ncbi.nlm.nih.gov/282450755 Brayton KM, Hirsch AT, O Brien PJ, Cheville A, Karaca-Mandic P, Rockson SG. Lymphedema prevalence and treatment benefits in cancer: impact of a therapeutic intervention on health outcomes and costs. PLoS One. 2014 Dec 3;9(12):e114597. doi: 10.1371/journal.pone.0114597. eCollection 2014. https://pubmed.ncbi.nlm.nih.gov/254703836 Hormes JM, Bryan C, Lytle LA, Gross CR, Ahmed RL, Troxel AB, Schmitz KH. Impact of lymphedema and arm symptoms on quality of life in breast cancer survivors. Lymphology. 2010 Mar;43(1):1-13. https://pubmed.ncbi.nlm.nih.gov/205528147 Meretoja TJ, Leidenius MHK, Tasmuth T, Sipilä R, Kalso E. Pain at 12 months after surgery for breast cancer. JAMA. 2014 Jan 1;311(1):90-92. doi: 10.1001/jama.2013.278795. Erratum in: JAMA. 2017 Apr 25;317(16):1693. https://pubmed.ncbi.nlm.nih.gov/243819698 Colagiuri B, Christensen S, Jensen AB, Price MA, Butow PN, Zachariae R. Prevalence and predictors of sleep difficulty in a national cohort of women with primary breast cancer three to four months postsurgery. J Pain Symptom Manage. 2011 Nov;42(5):710-20. doi: 10.1016/j.jpainsymman.2011.02.012. Epub 2011 May 26. https://pubmed.ncbi.nlm.nih.gov/216206489 Hayes SC, Johansson K, Stout NL, Prosnitz R, Armer JM, Gabram S, Schmitz KH. Upper-body morbidity after breast cancer: incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care. Cancer. 2012 Apr 15;118(8 Suppl):2237-49. doi: 10.1002/cncr.27467. Review. https://pubmed.ncbi.nlm.nih.gov/2248869810 Paskett ED, Dean JA, Oliveri JM, Harrop JP. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. J Clin Oncol. 2012 Oct 20;30(30):3726-33. doi: 10.1200/JCO.2012.41.8574. Epub 2012 Sep 24. Review. https://pubmed.ncbi.nlm.nih.gov/23008299